MYLK and gastric cancer: According to the survival analyses, the median survival time of GC patients with lower expression of MYLK, MYL9, LUM, and CAV1 was1.37, 1.41, 1.35, and 1.42 years; with higher expression of MYLK, MYL9, LUM, and CAV1, the median survival time was 1.06, 1.08, 1.15, and 1.06 years in TCGA database, respectively.